Contribution: Industrial Research Assistance Program – Contributions to Firms
Giiant Pharma Inc.
$345,000.00
The development of digestive tract-circumscribed PDE4 inhibitor prodrugs for the treatment of ulcerative colitis.
FY 2021-22 · 2021-08-02
Summary
Giiant Pharma develops new therapeutic for the gastrointestinal tract. The project aims to finalize the preclinical development and the production process to position the product for clinical trials.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
835958596
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-08-02 | 2021-22 | $500,000.00 |
| 1 | 2021-08-02 | 2021-22 | $345,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by -65 days. The total amended value is -155,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de -65 jours. La valeur totale des modifications est de - 155 000 dollars.
Agreement End Date
2022-05-31
Agreement Number
976749
Agreement Start Date
2021-08-02
Agreement Title
The development of digestive tract-circumscribed PDE4 inhibitor prodrugs for the treatment of ulcerative colitis.
Agreement Title (French)
Mise au point de promédicaments inhibiteurs de la phosphodiestérase 4 (PDE4) à l'échelle du tube digestif pour le traitement de la colite ulcéreuse
Agreement Type
Contribution
Agreement Value
$345,000.00
Amendment Date
2022-08-03
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Giiant Pharma develops new therapeutic for the gastrointestinal tract. The project aims to finalize the preclinical development and the production process to position the product for clinical trials.
Description (French)
Giiant Pharma met au point un nouveau produit thérapeutique pour le tractus gastro-intestinal. Le projet vise à finaliser le développement préclinique et le procédé de production afin de positionner le produit pour les essais cliniques.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding (French)
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number
24077
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
835958596
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
Giiant Pharma Inc.
Recipient Operating Name
Giiant Pharmaceutique
Recipient Postal Code
H3B 1S6
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2021-2022-Q2-976749
